Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment SAN FRANCISCO and TORONTO and ZURICH, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a pioneering biotech company dedicated to revolutionizing regenerative medicine, is...

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...

Endogena Therapeutics Completes Dose Escalation in the Phase 1/2a Clinical Trial of EA-2353 for the Treatment of Retinitis Pigmentosa SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous...

Endogena Therapeutics Receives US FDA Fast Track Designation for EA-2353 for the Treatment of Retinitis Pigmentosa SAN FRANCISCO, TORONTO and ZÜRICH, Switzerland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company focused on the development of endogenous...